Last updated: February 13, 2026
What is NDC 70000-0479?
NDC 70000-0479 is a drug marketed under the label "Vascepa," a prescription omega-3 fatty acid capsule. It is approved for cardiovascular risk reduction and hypertriglyceridemia. Developed by Amarin Corporation, Vascepa gained FDA approval in 2012 and has since been integrated into the treatment landscape for lipid management.
Market Size and Sales Performance
Current Market Context:
- Vascepa sales reached approximately $602 million in 2022, with steady growth from $497 million in 2021 (as per IQVIA data).
- The drug's primary indications cover patients with severe hypertriglyceridemia and those at high cardiovascular risk, a segment estimated at approximately 15 million patients in the U.S.
- The drug competes with fish oil supplements and other prescription therapies, such as Omega-3 acid ethyl esters (Vascepa's key competitor in the prescription omega-3 market).
Market Drivers:
- Expanding approval for broader indications, including cardiovascular risk reduction.
- Growing awareness of hypertriglyceridemia as a risk factor for cardiovascular disease.
- The launch and approval of generics or alternative therapies could impact market share.
Pricing Overview
Current Pricing:
- Average wholesale price (AWP): Approximately $300 per month per bottle (targeting a 30-day supply).
- Actual patient out-of-pocket costs can vary based on insurance coverage, with co-pay assistance programs reducing out-of-pocket burdens.
Pricing Trends:
- Since FDA approval, Vascepa's price has remained stable, with minor fluctuations tied to pricing negotiations, rebates, and discounts.
- The patent status, patent extensions, and litigation impact future pricing potential.
Insurance and Reimbursements:
- Reimbursement depends heavily on formulary placement and insurer negotiations.
- Prior to patent expiry or generic entry, Vascepa's price maintains a premium relative to non-prescription omega-3 supplements.
Regulatory and Patent Outlook
- Patent protection in the U.S. extends to at least 2023, with patent litigation ongoing.
- The potential entry of generic versions following patent expiration could reduce prices by up to 80%, as seen in other prescription drugs.
- FDA's approval of multiple generics may significantly alter the market landscape.
Future Price Projections
| Year |
Estimated Price Range (Monthly) |
Key Assumptions |
| 2023 |
$250 - $300 |
Patent life extension, steady demand, no generics yet |
| 2024 |
$200 - $250 |
Pending patent expiration, potential generic entry begins |
| 2025+ |
$50 - $150 |
Market saturation with generics, significant price erosion begins |
Factors influencing future prices include:
- Patent expiration date: expected around late 2023 or early 2024.
- Market penetration of generics: high likelihood of price erosion post-patent expiry.
- Regulatory decisions: approval of biosimilars or additional indications might sustain higher prices.
- Insurance coverage: broader coverage may dampen price sensitivity but not prevent generic competition.
Competitive Landscape
- Branded Prescriptions: Vascepa is the dominant brand under patents, with sales contagion from expanded indications.
- Generics: Multiple companies have filed Abbreviated New Drug Application (ANDA) submissions for generic versions, targeting patent expiry.
- Supplements: Over-the-counter omega-3 products, priced between $10–$50, compete on price but lack specific FDA approval for similar indications.
Risks and Market Challenges
- Patent litigation outcomes could either extend exclusivity or hasten generic entry.
- Pricing pressures from generics or biosimilars may reduce profit margins.
- Clinical trial results and regulatory decisions affecting indication breadth influence market acceptance.
- Reimbursement landscape uncertainties can affect net revenue.
Key Takeaways
- NDC 70000-0479, Vascepa, commands a premium price with $300/month averages, driven by brand loyalty and clinical positioning.
- The U.S. market for omega-3 lipid therapies is projected to grow, contingent on expanding indications and cardiovascular risk management trends.
- Patent expiration around 2023-2024 is expected to trigger substantial price declines, with generics possibly reducing prices by 70-80%.
- Market penetration of generics, insurance reimbursements, and regulatory decisions remain principal factors influencing future pricing.
- Current brand dominance and ongoing litigation are significant for short-term sales retention.
FAQs
1. When will generic versions of Vascepa likely enter the market?
Generic applications are likely approved by late 2023 or early 2024, following patent expiry, with market entry shortly thereafter.
2. How much could prices decline post-patent expiry?
Prices could fall by 70-80%, similar to trends observed with other branded pharmaceuticals once generics enter.
3. What therapeutic areas could expand Vascepa’s market?
Broader cardiovascular risk management, including additional indications for high triglycerides and residual cardiovascular risk.
4. How does insurance coverage impact Vascepa’s price?
Insurance and formulary negotiations influence patient out-of-pocket costs; rebates and copayment assistance mitigate high pricing.
5. What external factors could alter the price projections?
Regulatory rulings, patent litigation results, market competition, and reimbursement policies.
Sources
- IQVIA. "2022 Prescription Drug Sales Data."
- FDA. "Vascepa (icosapent ethyl) Approval Information."
- Amarin Corporation. "Financial Reports and Market Analysis."
- Analysis of generic drug filings and patent timelines from the FDA's Orange Book.
- Industry reports on prescription omega-3 market trends.
